Resultados da busca - Norbert Gattermann

Refinar Resultados
  1. 1
    Overview of guidelines on iron chelation therapy in patients with myelodysplastic syndromes and transfusional iron overload

    Overview of guidelines on iron chelation therapy in patients with myelodysplastic syndromes and transfusional iron overload por Norbert Gattermann

    Publicado em 2008
    Obter o texto integral Obter o texto integral
    Revisão
    Salvar na lista
    Na minha lista:
  2. 2
    The Treatment of Secondary Hemochromatosis

    The Treatment of Secondary Hemochromatosis por Norbert Gattermann

    Publicado em 2009
    Obter o texto integral
    Revisão
    Salvar na lista
    Na minha lista:
  3. 3
    Iron overload in myelodysplastic syndromes (MDS)

    Iron overload in myelodysplastic syndromes (MDS) por Norbert Gattermann

    Publicado em 2017
    Obter o texto integral Obter o texto integral
    Revisão
    Salvar na lista
    Na minha lista:
  4. 4
    Valproic acid for the treatment of myeloid malignancies

    Valproic acid for the treatment of myeloid malignancies por Andrea Kuendgen, Norbert Gattermann

    Publicado em 2007
    Obter o texto integral Obter o texto integral
    Carta
    Salvar na lista
    Na minha lista:
  5. 5
    Iron overload in MDS—pathophysiology, diagnosis, and complications

    Iron overload in MDS—pathophysiology, diagnosis, and complications por Norbert Gattermann, Eliezer A. Rachmilewitz

    Publicado em 2010
    Obter o texto integral
    Revisão
    Salvar na lista
    Na minha lista:
  6. 6
    Myelodysplastic Syndromes

    Myelodysplastic Syndromes por Peter L. Greenberg, Neal S. Young, Norbert Gattermann

    Publicado em 2002
    Obter o texto integral Obter o texto integral
    Revisão
    Salvar na lista
    Na minha lista:
  7. 7
    Myelodysplastic Syndromes

    Myelodysplastic Syndromes por Ulrich Germing, Guido Kobbe, Rainer Haas, Norbert Gattermann

    Publicado em 2013
    Obter o texto integral
    Revisão
    Salvar na lista
    Na minha lista:
  8. 8
    The evaluation of iron deficiency and iron overload

    The evaluation of iron deficiency and iron overload por Norbert Gattermann, Martina U. Muckenthaler, Andreas E. Kulozik, Georgia Metzgeroth, Jan Hastka

    Publicado em 2021
    Obter o texto integral
    Revisão
    Salvar na lista
    Na minha lista:
  9. 9
    Myelodysplastic Syndromes in Patients Younger Than Age 50

    Myelodysplastic Syndromes in Patients Younger Than Age 50 por Andrea Kuendgen, Corinna Strupp, Manuel Aivado, Barbara Hildebrandt, Rainer Haas, Norbert Gattermann, Ulrich Germing

    Publicado em 2006
    Obter o texto integral Obter o texto integral
    Artigo
    Salvar na lista
    Na minha lista:
  10. 10
    Heteroplasmic Point Mutations of Mitochondrial DNA Affecting Subunit I of Cytochrome c Oxidase in Two Patients With Acquired Idiopathic Sideroblastic Anemia

    Heteroplasmic Point Mutations of Mitochondrial DNA Affecting Subunit I of Cytochrome c Oxidase in Two Patients With Acquired Idiopathic Sideroblastic Anemia por Norbert Gattermann, Stefan Retzlaff, Yanling Wang, Götz Hofhaus, Jürgen J. Heinisch, Carlo Aul, Wolfgang Schneider

    Publicado em 1997
    Obter o texto integral Obter o texto integral
    Artigo
    Salvar na lista
    Na minha lista:
  11. 11
    High frequency of the JAK2 V617F mutation in patients with thrombocytosis (platelet count > 600 × 109/L) and ringed sideroblasts more than 15% considered as MDS/MPD, unclassifiable

    High frequency of the JAK2 V617F mutation in patients with thrombocytosis (platelet count > 600 × 109/L) and ringed sideroblasts more than 15% considered as MDS/MPD, unclassifia... por Norbert Gattermann, Johan Billiet, Ralf Kronenwett, E. Zipperer, Ulrich Germing, Friedel Nollet, A. Criel, Dominik Selleslag

    Publicado em 2007
    Obter o texto integral Obter o texto integral
    Carta
    Salvar na lista
    Na minha lista:
  12. 12
    Treatment of myelodysplastic syndromes with valproic acid alone or in combination with all-trans retinoic acid

    Treatment of myelodysplastic syndromes with valproic acid alone or in combination with all-trans retinoic acid por Andrea Kuendgen, Corinna Strupp, Manuel Aivado, A. Bernhardt, Barbara Hildebrandt, Rainer Haas, Ulrich Germing, Norbert Gattermann

    Publicado em 2004
    Obter o texto integral Obter o texto integral
    Artigo
    Salvar na lista
    Na minha lista:
  13. 13
    The hematopoietic stem cell transplantation comorbidity index is of prognostic relevance for patients with myelodysplastic syndrome

    The hematopoietic stem cell transplantation comorbidity index is of prognostic relevance for patients with myelodysplastic syndrome por E. Zipperer, D. Pelz, Kathrin Nachtkamp, A. Kuendgen, C. Strupp, Norbert Gattermann, Rainer Haas, Ulrich Germing

    Publicado em 2009
    Obter o texto integral Obter o texto integral
    Artigo
    Salvar na lista
    Na minha lista:
  14. 14
    Intensive chemotherapy is not recommended for patients aged >60 years who have myelodysplastic syndromes or acute myeloid leukemia with high‐risk karyotypes

    Intensive chemotherapy is not recommended for patients aged >60 years who have myelodysplastic syndromes or acute myeloid leukemia with high‐risk karyotypes por Sabine Knipp, Barbara Hildebrand, Andrea Kündgen, Aristoteles Giagounidis, Guido Kobbe, Rainer Haas, Carlo Aul, Norbert Gattermann, Ulrich Germing

    Publicado em 2007
    Obter o texto integral Obter o texto integral
    Artigo
    Salvar na lista
    Na minha lista:
  15. 15
    Platelet counts and haemorrhagic diathesis in patients with myelodysplastic syndromes

    Platelet counts and haemorrhagic diathesis in patients with myelodysplastic syndromes por Judith Neukirchen, Sabine Blum, Andrea Kuendgen, Corinna Strupp, Manuel Aivado, Rainer Haas, Carlo Aul, Norbert Gattermann, Ulrich Germing

    Publicado em 2009
    Obter o texto integral
    Artigo
    Salvar na lista
    Na minha lista:
  16. 16
    Chronic myelomonocytic leukemia in the light of the WHO proposals

    Chronic myelomonocytic leukemia in the light of the WHO proposals por Ulrich Germing, C. Strupp, S. Knipp, A. Kuendgen, Aristoteles Giagounidis, B. Hildebrandt, C. Aul, R Haas, Norbert Gattermann, John M. Bennett

    Publicado em 2007
    Obter o texto integral Obter o texto integral
    Artigo
    Salvar na lista
    Na minha lista:
  17. 17
    The histone deacetylase (HDAC) inhibitor valproic acid as monotherapy or in combination with all‐trans retinoic acid in patients with acute myeloid leukemia

    The histone deacetylase (HDAC) inhibitor valproic acid as monotherapy or in combination with all‐trans retinoic acid in patients with acute myeloid leukemia por Andrea Kuendgen, Mathias Schmid, Richard F. Schlenk, Sabine Knipp, Barbara Hildebrandt, Christian Steidl, Ulrich Germing, Rainer Haas, Hartmut Döhner, Norbert Gattermann

    Publicado em 2005
    Obter o texto integral
    Artigo
    Salvar na lista
    Na minha lista:
  18. 18
    Continued azacitidine therapy beyond time of first response improves quality of response in patients with higher‐risk myelodysplastic syndromes

    Continued azacitidine therapy beyond time of first response improves quality of response in patients with higher‐risk myelodysplastic syndromes por Lewis R. Silverman, Pierre Fenaux, Ghulam J. Mufti, Valeria Santini, Eva Hellström‐Lindberg, Norbert Gattermann, Guillermo Sanz, Alan F. List, Steven D. Gore, John F. Seymour

    Publicado em 2011
    Obter o texto integral Obter o texto integral
    Artigo
    Salvar na lista
    Na minha lista:
  19. 19
    Gene expression profiling identifies significant differences between the molecular phenotypes of bone marrow–derived and circulating human CD34+ hematopoietic stem cells

    Gene expression profiling identifies significant differences between the molecular phenotypes of bone marrow–derived and circulating human CD34+ hematopoietic stem cells por Ulrich Steidl, Ralf Kronenwett, Ulrich‐Peter Rohr, Roland Fenk, Slawomir Kliszewski, Christian Maercker, Peter Neubert, Manuel Aivado, J. H. Koch, Olga Modlich, Hans Bojar, Norbert Gattermann, Rainer Haas

    Publicado em 2002
    Obter o texto integral Obter o texto integral
    Artigo
    Salvar na lista
    Na minha lista:
  20. 20
    High-throughput sequencing screen reveals novel, transforming RAS mutations in myeloid leukemia patients

    High-throughput sequencing screen reveals novel, transforming RAS mutations in myeloid leukemia patients por Jeffrey W. Tyner, Heidi S. Erickson, Michael W. Deininger, Stephanie G. Willis, Christopher A. Eide, Ross L. Levine, Michael C. Heinrich, Norbert Gattermann, D. Gary Gilliland, Brian J. Druker, Marc Loriaux

    Publicado em 2008
    Obter o texto integral Obter o texto integral
    Artigo
    Salvar na lista
    Na minha lista:

Ferramentas de busca: